Research location

Al Ain City

United Arab Emirates

Published trials28

Site observations29

Linked trials published28

Page1 / 1

Research activity in Al Ain City

United Arab Emirates

CureCurrent currently publishes aggregate city-level research activity for this location: 28 trials and 29 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Al Ain City

28 linked trials · page 1 of 1

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307 · 2026-07-15 · 1 site observation

BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine TherapyNCT07597993 · 2026-07-12 · 1 site observation

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328 · 2026-06-15 · 1 site observation

HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation CouncilNCT06125314 · 2024-03-05 · 1 site observation

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation

ACTIVE_NOT_RECRUITING

Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma PatientsNCT05603845 · 2023-02-20 · 1 site observation

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC RegionNCT06039683 · 2022-12-31 · 1 site observation

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)NCT05296798 · 2022-07-18 · 1 site observation

ACTIVE_NOT_RECRUITING

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf RegionNCT04916509 · 2021-09-13 · 1 site observation

Impact of Long-term Serum Magnesium and Potassium Levels Optimization and Multifactorial Adherence Intervention on the Progression of Diabetic Kidney Disease.NCT04942119 · 2021-05-01 · 1 site observation

A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeNCT03782207 · 2019-02-07 · 1 site observation

Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to FulvestrantNCT03447132 · 2017-12-20 · 1 site observation

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)NCT03285763 · 2017-10-25 · 1 site observation

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.NCT02964247 · 2017-03-03 · 1 site observation

An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During RamadanNCT02737657 · 2016-04-01 · 1 site observation

Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North AfricaNCT02304406 · 2015-01-21 · 1 site observation

Global Non-interventional Heart Failure Disease RegistryNCT02595814 · 2014-07-23 · 1 site observation

Vit D to Treat Asthma in Children: a Randomized, Double-blind, Placebo-controlled TrialNCT01284907 · 2013-03-01 · 2 site observations

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentNCT01702571 · 2012-11-27 · 1 site observation

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerNCT01572038 · 2012-06-01 · 1 site observation

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerNCT01566721 · 2012-05-17 · 1 site observation

Skills for Change: Nutrition Education Program for Emirati Adults With Type 2 DiabetesNCT04264793 · 2011-11-20 · 1 site observation

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 DiabetesNCT01400971 · 2011-07-01 · 1 site observation

Africa and Middle East Cardiovascular Epidemiological StudyNCT01243138 · 2011-07-01 · 1 site observation

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT01351415 · 2011-06-25 · 1 site observation

AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung CancerNCT00961415 · 2009-08-01 · 1 site observation

Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast caNCT00944424 · 2009-07-01 · 1 site observation

Caduet vs Usual Care in Subjects With Hypertension and Additional Risk FactorsNCT00407537 · 2007-03-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.